Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11304940 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11612594 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11357764 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11376244 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11612593 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11426396 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11633387 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11357765 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11786516 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11826360 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(14 years from now) | |
US11622962 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(3 years from now) | |
US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
US10925866 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
US9999618 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
US10525045 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
US11033538 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
USRE48608 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
US9095584 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
US10813921 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
US8592362 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
US10799491 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10806727 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11278540 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11666564 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11357761 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11357762 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11357763 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11278538 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11278537 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11278536 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10857141 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10849890 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10849889 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10792278 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10792279 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10857142 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11813255 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10874656 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11389437 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11389436 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10251873 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10471053 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10874655 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US10874657 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11458128 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11278539 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
US11357784 | AMICUS THERAP US | Use of migalastat for treating Fabry disease in pregnant patients |
Feb, 2039
(14 years from now) | |
US11642334 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(14 years from now) | |
US11633388 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(14 years from now) | |
US11833164 | AMICUS THERAP US | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
Jan, 2042
(17 years from now) |
Galafold is owned by Amicus Therap Us.
Galafold contains Migalastat Hydrochloride.
Galafold has a total of 57 drug patents out of which 0 drug patents have expired.
Galafold was authorised for market use on 10 August, 2018.
Galafold is available in capsule;oral dosage forms.
Galafold can be used as the treatment of fabry patients, a method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat.
Drug patent challenges can be filed against Galafold from 10 August, 2022.
The generics of Galafold are possible to be released after 11 January, 2042.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat
Dosage: CAPSULE;ORAL